We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently.In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks. We previously covered 10 stocks with at least $20 million in insider spending recently.

Trump administration’s tariffs on goods imported from Canada and Mexico, as well as additional duties on China, took effect yesterday. As expected, the stock market reacted immediately. The technology index fell 1.2%, hitting its lowest point in almost four months, wiping out post-election gains, while blue-chip companies declined 1.5% or 650 points.

“Tariffs of these magnitude will drive both Canada and Mexico into a recession," JP Morgan analysts wrote in their daily Tuesday note, writes The Street. Analysts added that higher costs and supply-chain disruptions will affect U.S. growth and domestic stocks. The tariffs could impact $2.2 trillion of global trade and provoke economic slowdowns in the U.S.

Many analysts have downgraded their U.S. stock projections, believing that strong earnings in 2025 may be more challenging. The broader market index is expected to finish the year around 9% higher than in 2024, but that’s still lower than the early January forecast of 12.2%.

The biggest potential positive factor, many experts are banking on, is a productivity boost from AI and expected lower interest rates. Morgan Stanley’s Andrew Slimmon suggests that the adoption of AI could lead to a productivity boom, similar to what happened with the Internet in the late 1990s.

With market fluctuations and uncertainty at play, insider trading draws attention. Executives and insiders, who possess valuable insights into company strategies, plans, and future moves, may engage in trades worth examining. For example, when a CEO or CFO invests their own money in company stock, it can signal strong confidence in the company's potential.

Insider buying and selling can be influenced by a range of factors, so these actions should be evaluated in the broader context of a company’s financial health, industry trends, and overall market conditions. This underscores the importance of thorough research before making any investment. While insider trading activity can provide useful insights into a company’s potential, it should be considered alongside other key factors to help investors make well-informed decisions.

Today, we'll focus on stocks with at least $30 million in insider spending. We used Insider Monkey’s stock screener to find stocks where at least one insider purchase in the last five months was worth $30 million or more. While the total value of all insider purchases could be higher, we only looked at those over $30 million. Since more than 10 stocks met these criteria, we chose the top 10 with the largest insider purchases above $30 million.

Story Continues

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

For each stock, we provide details on the highest individual purchase, the number of insider purchases higher than $30 million over the last three months and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $30 million in insider spending recently.Immunovant (IMVT): Among Stocks Insiders Spent The Most Money On Recently

A closeup of a scientist working with a microscope in a biotech laboratory.

Immunovant, Inc. (NASDAQ:IMVT)

Highest Individual Purchase: $336,900,200.00

Number of Purchases Above $30 million: 1

Market Capitalization: $3.14 billion

Immunovant, Inc. (NASDAQ:IMVT) is a biotechnology company focused on developing new treatments for autoimmune disorders. Known for its pioneering work in anti-FcRn technology, the company is creating innovative, targeted therapies aimed at improving the lives of individuals with various autoimmune diseases.

In the third quarter of 2024, Immunovant, Inc. (NASDAQ:IMVT) announced that five investigational new drug applications for its leading drug, IMVT-1402, had been cleared by the FDA across multiple therapeutic areas and divisions. The company also stated that it is on track to begin the registration trial for IMVT-1402 across several indications by the end of March this year.

On January 13, one insider bought $336.9 million worth of Immunovant shares for $20 per share. This way, Roivant Sciences Ltd. increased its holdings to 96.65 million shares. This purchase was part of the company’s $450 million private placement.

Currently, the stock is trading at $18.49 per share, having lost 25.35% year-to-date. Over the past 12 months, its stock price dropped 45.57%.

As of December 31, 2024, Immunovant, Inc. (NASDAQ:IMVT) had cash and cash equivalents amounting to $374.7 million. In the third quarter of 2024, the company reported a net loss of $111.1 million or $0.76 per share, which compares to a net loss of $51.4 million or $0.36 per share for the same quarter in 2023.

Thirteen analysts have an average “Moderate Buy” rating on Immunovant, Inc. (NASDAQ:IMVT) stock, with a price target of $43.35, according to MarketBeat.

Immunovant is also one of the 10 oversold pharma stocks to buy according to analysts.

Overall IMVT ranks 2nd on our list of the stocks with at least $30 million in insider spending recently. While we acknowledge the potential of IMVT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IMVT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.

View Comments